Citius to advance Mino-Lok Phase 3 Trial under COVID-19 compliance.

Global Banking News-September 16, 2020-Citius to advance Mino-Lok Phase 3 Trial under COVID-19 compliance

(C)2020 ENPublishing - http://www.enpublishing.co.uk

Pharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR) announced on Tuesday that it has filed an amendment to its Mino-Lok phase 3 protocol to allow for more efficient follow-up and record-keeping of required clinical trial documentation given COVID-19 restrictions.

Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge.

Following the restrictions of personal visits, the company has issued instructions in the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT